PubMed Health⌕ Search

Biomedical subjects

Guorong Li

Publications and source records attributed to Guorong Li.

21 records · Page 2Linked to original sources

Preliminary in vivo study of an intra-aortic impeller pump driven by an extracorporeal whirling magnet.

To achieve the aim of long-term heart-assist with a simple implantable device, we have been trying to develop a minimal intra-aortic impeller blood pump driven by an extracorporeal magnetic device. The purpose of the current study was to evaluate its feasibility by acute in vivo animal tests. The minimal intra-aortic pump was a cage-supported rotor-impeller, 17 mm in diameter with a total length of 30 mm. The driving magnet, mounted extracorporeally, was 55 mm in diameter and 50 mm in length. Seventeen dogs weighing from 28-34 kg were used in the study. After thoracic incision, heparin (50 U/kg) was infused. The impeller pump was inserted into the aortic chamber via a prosthetic vessel and fastened. Thin tubes were inserted into the left ventricular apex and the femoral artery to monitor the left ventricular (LV) and the aortic pressure. After closing the thoracic cavity, the extracorporeal whirling magnet, turned by an electric motor, was placed tightly against the thoracic wall parallel to the intra-aortic pump. The experiments, each lasting for about 40 min, were successful in 7 animals; the other 10 animals died of bleeding during pump implantation and were excluded from the experiment. The peak systolic pressure of the left ventricle could be considerably decreased by the pump and was reduced to as low as 28 mm Hg at a rotational speed of 9,000 rpm, showing that the simple intra-aortic impeller was effective in unloading the natural heart. The novel left ventricular assist device (LVAD) concept of an intra-aortic impeller pump, driven by an extracorporeal magnetic device, is feasible.

Animals↗

The in vivo DNA aneuploidization during expansion of conventional renal cell carcinoma.

Although numerous studies on the prognostic value of DNA aneuploidy in RCC have been reported, the in vivo DNA aneuploidization during RCC expansion has not been revealed. The present study was undertaken to observe the DNA aneuploidization during RCC expansion. We studied prospectively 67 consecutive conventional RCCs. The ploidy status was determined by analyzing five fresh tumor tissues from different areas by flow cytometry. The diploid, heterogeneous aneuploid tumors and homogeneous aneuploid tumors could be detected, respectively, in 44.8%, 23.9% and 31.3% of cases. The diploid tumors decreased significantly and aneuploid tumors increased significantly as the tumor expanded. The similar DNA content distribution was found between the heterogeneous aneuploid tumors and homogeneous aneuploid tumors. The hypertriploid clone was the most frequent in aneuploid tumors. The tumors of multiple aneuploid clones (16.4%) were mainly found in large-sized tumors. These results suggested that some RCCs underwent DNA aneuploidization during the tumor expansion and that a major route of aneuploidiztion (hypertriploidization) and several pathways existed. Our results also supported the idea that the progressive chromosomal instability was associated with continued tumor growth of RCC. The molecular mechanism and the clinical significance of aneuploidy phenotypes need to be further investigated.

Aneuploidy↗

Cadherin-6 gene expression in conventional renal cell carcinoma: a useful marker to detect circulating tumor cells.

BACKGROUND: Dissemination of cancer cells into the circulation is an essential step in the development of a metastasis. Detection of circulating cancer cells may improve the monitoring methods for cancer patients. However, the detection of circulating renal cancer cells is mainly hampered by the lack of markers available for renal cell carcinoma (RCC). In this study, we evaluated cadherin-6 mRNA as a new molecular marker for the detection of circulating renal cancer cells. MATERIALS AND METHODS: Forty-six blood samples of conventional RCCs were included. A standard protocol of RT-PCR, assisted by computer densitometric analysis to establish a cut-off, was performed to examine cadherin-6 mRNA expression by using specific primers. A renal cancer cell line, SKRC-59 and forty tumor biopsies from conventional RCCs were used as positive controls. Twenty-five blood samples from non-RCC patients were also analyzed. RESULTS: Cadherin-6 mRNA could be detected in 38140 (95%) conventional RCC specimens. Cadherin-6 mRNA was positive in 21/46 (45.7%) blood samples of RCC patients, while no positivity was found in non-RCC blood samples. Among the localized RCCs, 14/35 (40.0%) blood samples were positive while 7/11 (63.6%) were positive among the blood samples from metastatic RCCs. CONCLUSION: Our data indicate that cadherin-6 gene is frequently expressed in conventional RCCs. Cadherin-6 is a useful molecular marker to detect the circulating cancer cells disseminated from conventional RCC.

Biomarkers, Tumor↗